Fig. 2

Training set RFS by 2022 ELN, cure status (A–C), and susceptibility to relapse (D–F). A Kaplan–Meier curves for relapse-free survival for 2022 ELN Favorable risk patients in the training set stratified by those predicted to be cured versus susceptible to relapse or death using the semi-parametric penalized MCM. B Kaplan–Meier curves for relapse-free survival for 2022 ELN Intermediate risk patients in the training set stratified by those predicted to be cured versus susceptible using the semi-parametric penalized MCM. C Kaplan–Meier curves for relapse-free survival for 2022 ELN Adverse risk patients in the training set stratified by those predicted to be cured versus susceptible using the semi-parametric penalized MCM. D Kaplan–Meier curves for relapse-free survival for 2022 ELN Favorable risk patients predicted to be susceptible in the training set using the semi-parametric penalized MCM, stratified by high versus low risk of relapse. E Kaplan–Meier curves for relapse-free survival for 2022 ELN Intermediate risk patients predicted to be susceptible in the training set using the semi-parametric penalized MCM, stratified by high versus low risk of relapse. F Kaplan–Meier curves for relapse-free survival for 2022 ELN Adverse risk patients predicted to be susceptible in the training set using the semi-parametric penalized MCM, stratified by high versus low risk of relapse